| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Dopamine D2-like receptors, with highest affinity for D2 (Ki ≈ 0.09 nM), and lower affinity for α1-adrenergic (Ki ≈ 112 nM), α2-adrenergic (Ki ≈ 699 nM), 5-HT1 (Ki ≈ 6220 nM), and 5-HT2 (Ki ≈ 830 nM) receptors. It competitively blocks dopamine binding at D2-like receptors.
|
|---|---|
| ln Vitro |
Eticlopride binds D2 receptors with a Ki of approximately 0.09 nM, showing high selectivity over α1-adrenergic, α2-adrenergic, 5-HT1, and 5-HT2 receptors. It is a potent D2-like antagonist and is used as a reference ligand in dopamine receptor binding assays and PET imaging studies.
|
| ln Vivo |
In vivo, eticlopride produces antipsychotic-like and extrapyramidal effects in animal models, consistent with D2 receptor blockade. It is used in PET imaging studies to quantify D2 receptor availability. Its pharmacokinetics and behavioral effects are characterized in preclinical studies.
|
| Enzyme Assay |
In vitro receptor binding assays use membranes expressing recombinant D2, D3, or D4 receptors and a radiolabeled antagonist such as [³H]spiperone or [³H]raclopride. Compound is serially diluted, and displacement is measured by filtration. Ki values are calculated from IC50 values.
|
| Cell Assay |
In vitro cell-based assays use D2 receptor-expressing cells and measure dopamine-induced cAMP inhibition or β-arrestin recruitment. Compound is pre-incubated, and antagonist activity is quantified by reversal of dopamine-mediated signaling. Functional selectivity at D2 versus D3 can be assessed.
|
| Animal Protocol |
In vivo animal experiments use rodents in behavioral models such as apomorphine-induced stereotypy, catalepsy, or conditioned avoidance. Eticlopride is administered intraperitoneally or subcutaneously at doses guided by pharmacokinetic studies, and behavioral scores are recorded. PET imaging can quantify D2 receptor occupancy in the brain.
|
| References | |
| Additional Infomation |
5-Chloro-3-ethyl-N-[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-2-hydroxy-6-methoxybenzamide is one of the salicylamide compounds.
|
| Molecular Formula |
C17H25N2O3CL.HCL
|
|---|---|
| Molecular Weight |
377.30594
|
| Exact Mass |
376.132
|
| CAS # |
84226-12-0
|
| Related CAS # |
97612-24-3 (HCl); 84226-12-0;
|
| PubChem CID |
57267
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.173g/cm3
|
| Boiling Point |
430.8ºC at 760 mmHg
|
| Flash Point |
214.4ºC
|
| Index of Refraction |
1.548
|
| LogP |
3.961
|
| tPSA |
61.8
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
23
|
| Complexity |
396
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CCC1=CC(=C(C(=C1O)C(=O)NCC2CCCN2CC)OC)Cl
|
| InChi Key |
AADCDMQTJNYOSS-LBPRGKRZSA-N
|
| InChi Code |
InChI=1S/C17H25ClN2O3/c1-4-11-9-13(18)16(23-3)14(15(11)21)17(22)19-10-12-7-6-8-20(12)5-2/h9,12,21H,4-8,10H2,1-3H3,(H,19,22)/t12-/m0/s1
|
| Chemical Name |
5-chloro-3-ethyl-N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-2-hydroxy-6-methoxybenzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6503 mL | 13.2517 mL | 26.5034 mL | |
| 5 mM | 0.5301 mL | 2.6503 mL | 5.3007 mL | |
| 10 mM | 0.2650 mL | 1.3252 mL | 2.6503 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.